EA201591783A1 - Использование sdf-1 для уменьшения образования рубцов - Google Patents

Использование sdf-1 для уменьшения образования рубцов

Info

Publication number
EA201591783A1
EA201591783A1 EA201591783A EA201591783A EA201591783A1 EA 201591783 A1 EA201591783 A1 EA 201591783A1 EA 201591783 A EA201591783 A EA 201591783A EA 201591783 A EA201591783 A EA 201591783A EA 201591783 A1 EA201591783 A1 EA 201591783A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sdf
education
wound
reduce scroll
protein
Prior art date
Application number
EA201591783A
Other languages
English (en)
Other versions
EA031883B1 (ru
Inventor
Марк С. Пенн
Мэттью Кидровски
Рахул Арас
Джозеф Пастор
Original Assignee
Джувентас Терапьютикс, Инк.
Дзе Кливленд Клиник Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джувентас Терапьютикс, Инк., Дзе Кливленд Клиник Фаундейшн filed Critical Джувентас Терапьютикс, Инк.
Publication of EA201591783A1 publication Critical patent/EA201591783A1/ru
Publication of EA031883B1 publication Critical patent/EA031883B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Представленный здесь объект изобретения относится к способу ингибирования и/или снижения образования рубцов в ране кожи методом повышения концентрации SDF-1 в ране или вблизи раны. Описанные здесь белок SDF-1 или вектор экспрессии SDF-1 могут быть введены в рану или область вблизи раны методом предоставления терапевтически эффективного количества белка SDF-1 или вектора экспрессии SDF-1.
EA201591783A 2013-03-15 2014-03-15 Способ ингибирования и/или снижения образования рубцовой ткани EA031883B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793462P 2013-03-15 2013-03-15
PCT/US2014/029960 WO2014145236A2 (en) 2013-03-15 2014-03-15 The use of sdf-1 to mitigate scar formation

Publications (2)

Publication Number Publication Date
EA201591783A1 true EA201591783A1 (ru) 2016-01-29
EA031883B1 EA031883B1 (ru) 2019-03-29

Family

ID=51538437

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591783A EA031883B1 (ru) 2013-03-15 2014-03-15 Способ ингибирования и/или снижения образования рубцовой ткани

Country Status (12)

Country Link
US (1) US20160331809A1 (ru)
EP (1) EP2968436A4 (ru)
JP (1) JP2016516071A (ru)
KR (1) KR20160005333A (ru)
CN (1) CN105263507A (ru)
AU (1) AU2014233266A1 (ru)
BR (1) BR112015022010A2 (ru)
CA (1) CA2905145A1 (ru)
EA (1) EA031883B1 (ru)
IL (1) IL240837A0 (ru)
MX (1) MX2015012580A (ru)
WO (1) WO2014145236A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6581208B2 (ja) * 2014-12-23 2019-09-25 イリヤ ファーマ エービー 創傷治癒の方法
CN105250994A (zh) * 2015-10-29 2016-01-20 广州赛莱拉干细胞科技股份有限公司 一种促进皮肤伤口愈合的制剂及其制备方法和应用
KR101921727B1 (ko) * 2016-12-28 2018-11-23 주식회사 제네웰 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제
WO2019126706A1 (en) * 2017-12-21 2019-06-27 The General Hospital Corporation Chemorepellent agents in the treatment of immune-related skin disorders
CN109350767A (zh) * 2018-09-17 2019-02-19 陈元峰 一种趋化内源性细胞及诱导成软骨分化的生物活性支架及其用途
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JP2004016084A (ja) * 2002-06-14 2004-01-22 Mitsubishi Chemicals Corp 新規蛋白質およびそれをコードするｄｎａ
JP5031370B2 (ja) * 2004-09-17 2012-09-19 セルジェンテック株式会社 外用皮膚潰瘍治療剤
US7405195B2 (en) 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
AU2008338525B2 (en) * 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
CN102421894A (zh) * 2009-04-21 2012-04-18 迈阿密大学 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法
AU2010286511B2 (en) * 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
JP5896624B2 (ja) * 2011-05-13 2016-03-30 オリンパス株式会社 ホタル由来ルシフェラーゼ

Also Published As

Publication number Publication date
MX2015012580A (es) 2016-04-27
EA031883B1 (ru) 2019-03-29
US20160331809A1 (en) 2016-11-17
CN105263507A (zh) 2016-01-20
BR112015022010A2 (pt) 2017-08-29
WO2014145236A2 (en) 2014-09-18
EP2968436A2 (en) 2016-01-20
KR20160005333A (ko) 2016-01-14
JP2016516071A (ja) 2016-06-02
CA2905145A1 (en) 2014-09-18
EP2968436A4 (en) 2016-10-26
IL240837A0 (en) 2015-10-29
AU2014233266A1 (en) 2015-10-22
WO2014145236A3 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EA201591783A1 (ru) Использование sdf-1 для уменьшения образования рубцов
EA201791775A1 (ru) Цистеиновая протеаза
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12019501763A1 (en) Method of reducing neutropenia
PH12015502075B1 (en) Treatment of cataplexy
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
IN2014DE00193A (ru)
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201791424A1 (ru) Получение белка
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
MY163257A (en) Humanised anti-cd52 antibodies
HK1211471A1 (en) Treating th2-mediated diseases by inhibition of bromodomain- comprising proteins brd7 and brd9 brd7 brd9 th2
EA201592203A1 (ru) Способы лечения таупатии
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
PH12018501443A1 (en) Methods of administering hepcidin
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
EA032501B9 (ru) Способы и композиции для содействия заживлению острой раны и хронической раны
HK1260897A1 (zh) 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法
ZA201603098B (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
PH12019501358A1 (en) Methods of administering hepcidin

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU